Progen Co (XKRX:296160) Change In Receivables : ₩-336.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Progen Co Change In Receivables?

Progen Co's change in receivables for the quarter that ended in Dec. 2024 was ₩-336.0 Mil. It means Progen Co's Accounts Receivable increased by ₩336.0 Mil from Dec. 2023 to Dec. 2024 .

Progen Co's change in receivables for the fiscal year that ended in Dec. 2024 was ₩-336.0 Mil. It means Progen Co's Accounts Receivable increased by ₩336.0 Mil from Dec. 2023 to Dec. 2024 .

Progen Co's Accounts Receivable for the quarter that ended in Dec. 2024 was ₩0.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Progen Co's Days Sales Outstanding for the six months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Progen Co's liquidation value for the six months ended in Dec. 2024 was ₩-86,456.7 Mil.

Progen Co Change In Receivables Historical Data

The historical data trend for Progen Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progen Co Change In Receivables Chart

Progen Co Annual Data

Trend

Dec23

Dec24

Change In Receivables

-7,113.86

-336.03

Progen Co Semi-Annual Data
	Dec23	Dec24
Change In Receivables	-7,113.86	-336.03

Progen Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-336.0 Mil.

Progen Co (XKRX:296160) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Progen Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	682.717	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Progen Co's accounts receivable are only considered to be worth 75% of book value:

Progen Co's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1729.613	-	88186.354	+	0.75 * 0	+	0.5 * 0
=	-86,456.7

Progen Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Progen Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Progen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Magokjungang-ro, 7th Floor, Bio Innovation Park, Gangseo-gu, Seoul, KOR

Website

http://www.progen.co.kr

Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.

Progen Co Headlines

No Headlines